AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
MILAN, October 7, 2025 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, announced three presentations at the European Society of Gene & Cell Therapy 32nd Annual Meeting (ESGCT), […]
